Accrufer is owned by Shield Tx.
Accrufer contains Ferric Maltol.
Accrufer has a total of 3 drug patents out of which 0 drug patents have expired.
Accrufer was authorised for market use on 25 July, 2019.
Accrufer is available in capsule;oral dosage forms.
Accrufer can be used as method of treating iron deficiency.
Drug patent challenges can be filed against Accrufer from 2023-07-26.
The generics of Accrufer are possible to be released after 23 October, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(8 years from now) | |
US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 2023-07-26
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE;ORAL
6
Japan
5
United States
5
United Kingdom
4
China
4
European Union
3
Australia
3
Canada
2
Singapore
2
Spain
2
Korea, Republic of
1
Israel
1
South Africa
1
IB
1
Mexico
1
Saudi Arabia
1
Slovenia
1
Brazil
1
Poland
1
Chile
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic